Rosa & Co. Presents Record Number of Research Results at the Eighth American Conference on Pharmacometrics (ACoP8)
Will offer stay-at-homers event coverage via Twitter (#ACOP8)
SAN CARLOS, Calif., Oct. 4, 2017 /PRNewswire/ -- Rosa & Co., LLC announced today that they will be presenting a record 12 research posters and presentations at the eighth American Conference on Pharmacometrics (ACoP8), to be held in Fort Lauderdale, FL, on October 15–18, 2017.
In recent years, the adoption of Quantitative Systems Pharmacology (QSP) has increased significantly. This drug discovery and development modeling technique is used to reduce risks inherent throughout a pharmaceutical product's lifecycle. Rosa's PhysioPD™ Research Platform is a QSP approach that translates biology into interactive computer simulations that represent physiology, disease, and intervention effects. The PhysioPD Platform is used to test hypotheses and provide scientific insights—from target validation through preclinical and clinical development, and beyond—which are not possible through traditional research methods.
Led by Dr. Christina Friedrich, Chief Engineer, and Dr. Mike Reed, Chief Scientist, Rosa will present results from joint client research efforts in the immuno-oncology, diabetes, and autoimmune disease fields, including urea cycle disorder and psoriasis. The results demonstrate how different virtual patient strategies can be used to gain unique insights, de-risk drug discovery and development, and support better decision making. A complete list of Rosa posters and presentations can be downloaded from the Rosa website.
"I am excited to see the growth of our industry and see Rosa's position as the leading resource for QSP," said Founder, Chairman, and CEO Ron Beaver, PhD. "We recently increased our Twitter presence to bring news about QSP and other types of mathematical modeling to the community. You can follow the news at @RosaQSP or, during the event, look for the hashtag #ACOP8."
About Rosa
Rosa & Co was established in 2002 and has an extensive track record of partnerships with pharmaceutical and biopharmaceutical clients worldwide, reducing research and development risk, optimizing the use of program resources, and prioritizing candidate targets. PhysioPD Research, Rosa's proprietary Quantitative Systems Pharmacology approach, is an established scientific process that translates biology into an interactive computer simulation model, representing physiology, disease, and intervention effects; in essence, a fit-for-purpose PhysioPD Research Platform.
Rosa works with client project teams to complement their work by developing a PhysioPD Research Platform for the disease of interest. The resulting resource incorporates the joint project team's scientific interpretation of existing data and their most relevant hypotheses to address biological uncertainties.
Rosa's PhysioPD Research Platforms optimize the evaluation of novel targets and compounds, test the effects of new combination therapies, guide study and trial designs, and inform competitive differentiation. Rosa is also unique in its breadth and depth of disease area expertise—metabolic, cardiovascular, and inflammatory diseases; oncology and immuno-oncology; immune dysfunctions; central nervous system disorders; antibacterial/antiviral biology; and dermatology. For more information, visit www.rosaandco.com.
Media contact:
Patrick van der Valk
Senior Director of Marketing
Email: [email protected]
Phone: 415 692-5258
751 Laurel St., Suite 127
San Carlos, CA 94070-3113
www.rosaandco.com
SOURCE Rosa & Co
Share this article